コージェント・バイオサイエンス
Cogent Biosciences, Inc.
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -0.52 | $0 | -$78M |
| 2026 Q1 | -0.57 | $0 | -$87M |
| 2025 Q4 | -0.64 | $0 | -$80M |
| 2025 Q3 | -0.58 | $0 | -$64M |
| 2025 Q2 | -0.65 | $0 | -$55M |
| 2025 Q1 | -0.63 | $0 | -$67M |
| 2024 Q4 |
| -0.61 |
| $0 |
| -$61M |
| 2024 Q3 | -0.64 | $0 | -$52M |